Articles tagged with Ovarian Cancer
A recent study found that dietary isoflavone intake was associated with an elevated risk of advanced prostate cancer, but not non-advanced cases. Isoflavones are a type of phytoestrogen found in soybeans and other plants.
Zepsyre, a marine-derived anticancer drug, will be commercialized in South Korea under the deal. PharmaMar retains exclusive production rights and will sell to Boryung Pharm for commercial use.
A new blood test has been developed to detect ovarian cancer with high accuracy, using microRNA profiling to distinguish between cancerous and benign tumors. The test shows promise in accurately predicting ovarian cancer, even when other methods fail.
Researchers discovered that tumor cells in the fallopian tubes of women at high-risk for ovarian cancer can be detected years before they develop into the disease, providing a potential window of time for early detection and intervention. The study identified TP53 gene mutations as an early indicator of ovarian cancer development.
A study of nine women suggests that ovarian tumors may originate in the fallopian tubes, providing insights into cancer origin and potential prevention strategies. The researchers found identical genetic errors in chromosome 17 and BRCA genes in all patients, supporting the fallopian tube theory.
A study analyzing BRCA testing trends from 2003 to 2014 found a significant spike in testing following the publication of Angelina Jolie's op-ed on gene testing. The test increased 80-fold, with rural areas showing higher follow-up surgical procedure rates compared to urban areas.
A new study suggests that many pelvic tumors in women may have a common origin in the fallopian tubes, which could lead to new strategies for preventing and early detecting ovarian cancer. The research found that ovarian cancer cells share genetic similarities with cells covering the tips of fallopian tubes.
A recent study led by Mayo Clinic researchers found that tumor-infiltrating lymphocytes present in high-grade ovarian cancer tumors can predict patient survival. The study analyzed over 5,500 patients from nine countries and discovered that higher levels of these immune cells were associated with better outcomes.
Yale researchers have identified the molecular mechanism driving BRCA1 gene mutations' association with breast cancer, offering hope for personalized treatment plans and increased cancer detection accuracy.
A nanotechnology-enhanced biochip developed by NJIT engineer Eon Soo Lee can detect deadly diseases such as ovarian cancer and pneumonia early in their progression. The device, which analyzes a tiny amount of blood within two minutes, has the potential to improve treatment outcomes significantly.
Researchers at Notre Dame's Harper Cancer Research Institute have made a breakthrough in understanding how ovarian cancer cells spread throughout the body. They found that a specific membrane proteinase called MT1-MMP plays a crucial role in regulating the transition of cancer cells from floating to sticking phases.
A study published at ESMO 2017 Congress found that abdominal fat distribution is a significant predictor of cancer diagnosis in postmenopausal women. The study, which included 5,855 women, showed that the ratio of abdominal to peripheral fat was an independent risk factor for certain cancers.
The ARIEL3 trial shows rucaparib maintenance therapy significantly improves progression-free survival in patients with high-grade ovarian cancer and BRCA mutations. The medication also benefits patients with homologous recombination deficient tumors, increasing overall response rates.
The ICON8 trial confirms standard dosing of paclitaxel is safe and effective for European patients with ovarian cancer. The study found no benefit to dose-dense regimens in terms of progression-free survival, but noted a slight increase in grade 3-4 toxicity.
Despite high-risk genetic mutations detectable through simple blood or saliva tests, only 15% of affected women in US have taken recommended genetic test. A new study from UCLA Fielding School of Public Health highlights a significant unmet need for genetic testing across the country.
Researchers at The Wistar Institute have discovered a potential new therapeutic strategy for ovarian clear cell carcinoma, a difficult-to-treat form of ovarian cancer. By targeting the activity of histone deacetylase 6, a protein that suppresses tumor suppressive functions, they were able to increase apoptosis in tumor cells and reduce...
A new study offers a decision-analytic model to help women with BRCA mutations determine the optimal age for preventive surgeries that can significantly reduce lifetime breast and ovarian cancer risk. The model recommends specific ages for bilateral mastectomy (BM) and salpingo-oophorectomy (BSO) procedures.
Researchers from UT Health San Antonio found that BRCA1 mutation carriers experience higher gene expression-related stress in luminal epithelial cells, which are more prone to breast tumors. This stress is also associated with estrogen-responsive genes in the breasts and ovaries, a key site for cancer predisposition.
A new study from Duke University Medical Center questions the effectiveness of risk-reducing mastectomy for women with BRCA mutations who have already had ovarian cancer. The procedure is found to be cost-effective only for women diagnosed between 40-50 years old and at least five years post-ovarian cancer diagnosis.
A large population study found that female cancer survivors are 38% less likely to achieve a pregnancy than women in the general population. The detrimental effect on fertility was evident in almost all types of cancer diagnosed, with variations between different cancer diagnoses.
A new CT Perfusion technology has been developed to measure blood flow and predict how well ovarian cancer patients will respond to treatment. The study found that a decrease in blood flow is associated with longer survival times, while an increase is linked to shorter survival times.
A team of researchers at Fred Hutchinson Cancer Center will use recent technological advances in proteogenomics to identify biomarkers predicting treatment response and novel therapeutic targets for ovarian cancer. The goal is to improve understanding of drug resistance and ultimately enhance patient outcomes.
A study analyzing genetic test results, family histories, and disease status of nearly 95,600 women found that eight mutations are positively associated with breast cancer, while eleven are linked to ovarian cancer. The research provides clarity on the relative risk of developing cancer for women carrying these mutations.
A study published in Oncogene has shed new light on the molecular mechanisms of ovarian cancer spread. Researchers found that N-cadherin plays a key role in metastasis by enabling cancer cells to anchor to new sites in the body, and that disrupting this process may provide a therapeutic strategy.
Researchers at the University of Oxford have discovered that cancer cells manipulate a natural cell process called nonsense-mediated decay (NMD) to promote their survival. By understanding how NMD affects different types of cancer, scientists may be able to develop new treatments and therapies to control tumour growth.
A study of nearly 10,000 women with BRCA1 and BRCA2 mutations found age-specific breast and ovarian cancer risks that vary by mutation location and family history. The findings indicate a need for individualized counseling incorporating both family history profiles and mutation location to inform preventive strategies.
A new study by Mayo Clinic researchers found that women who experienced physical, emotional, or sexual abuse are 62% more likely to have their ovaries removed before age 46. The study suggests that gynecological symptoms such as abdominal pain or excessive bleeding may lead to unnecessary and harmful surgeries.
The study shows that open-access BRCA testing to Ashkenazi women enables the identification of carriers who would otherwise have been missed. Carrying one of the mutations for the BRCA genes means that women affected have a 50-80% risk of developing breast cancer and a 20-50% risk for ovarian cancer.
A study of over 48,000 stored tumor samples reveals that deficiencies in DNA repair mechanisms are common across various solid tumor types. The most commonly mutated genes were ATM, PTEN, BRCA2, BRCA1, and ATRX, which could lead to targeted therapies, including PARP inhibitors.
Researchers have identified a new combination therapy that may improve survival for women with ovarian cancer by eradicating chemotherapy-resistant tumors. The treatment, involving carboplatin and birinapant, showed promise in mice and human tumor models, with 50% of samples responding to the therapy.
Scientists are working on tweaking T-cell therapy for leukemia to apply to solid tumors like ovarian cancer. The researchers identified proteins overproduced by ovarian cancer cells and found that engineered T cells can kill both human and mouse ovarian cancer cells in the lab.
PharmaMar has reported new data on the mechanism of action of plitidepsin and lurbinectedin, two compounds being investigated for their potential to treat multiple myeloma and ovarian cancer. The study demonstrates the capacity of lurbinectedin to reverse cisplatin resistance in ovarian cancer cells.
Researchers have developed a new imaging test that can measure Poly (ADP-ribose) Polymerase 1 (PARP-1) levels in ovarian cancer patients, helping doctors identify those most likely to benefit from emerging PARP inhibitor therapy. The study used a novel radiotracer technology and PET scans to confirm findings in patients.
A combination of a PARP inhibitor and a kinase inhibitor showed significant tumor shrinkage in 36% of patients with platinum-resistant ovarian cancer, a surprising improvement over solo PARP inhibitor treatment. The treatment was well-tolerated, with four patients discontinuing due to toxicity.
A genome-wide analysis identified 30 known risk variants, accounting for 6.5% of the inherited component of risk. The variants are common and have small effects on risk, with women carrying multiple variants still having a low lifetime risk of 2.8%.
Researchers found that over 60% of BRCA tests performed on unaffected women have increased since 2004, mainly driven by marketing efforts. However, study findings suggest that this trend may not lead to better diagnosis of those at risk, as many women without harmful mutations are still being tested.
A new study found that the proportion of women without a history of cancer who underwent BRCA testing rose sharply from 2004 to 2014. However, many high-risk patients remain unidentified, highlighting the need for effective testing strategies to maximize detection of mutation carriers.
Researchers have identified a protein biomarker, CD151, expressed on tumour cells of high-grade serous ovarian cancer, which is linked to poor prognosis. The study provides new information about possible targets for ovarian cancer treatment and has the potential to develop a clinical screening tool.
Research at the University of Illinois Chicago found that blocking a protein on ovarian cancer cells can prevent its spread to other organs. The study's lead researcher believes this discovery could be a key to developing new treatments for the disease.
TGen researchers will test triptolide as a potential drug targeting SCCOHT, an aggressive form of ovarian cancer that affects mostly girls and young women. The grant aims to improve the understanding of ovarian cancer biology and potentially develop new treatments for this devastating disease.
A personalized strategy involving frequent CA125 blood tests and ultrasound examinations could improve the chance of detecting tumors at early stages. This approach reduced the risk of diagnosis with advanced cancer in high-risk women who chose to delay recommended preventive surgery.
Researchers found that hormonal maintenance therapy significantly improved survival in women with low-grade serous carcinoma of the ovary/peritoneum. Women who received HMT showed an average progression-free survival of 64.9 months, compared to 26.4 months for those in the surveillance group.
Researchers developed a new tool to analyze genetic changes in ovarian cancer, revealing pathways disrupted by the loss and gain of genes. The study found that targeting autophagy genes showed promise in treating chemotherapy-resistant disease.
Researchers will utilize a unique odor signature to create a portable screening device for early-stage ovarian cancer diagnosis. The project aims to improve survival rates by identifying the disease at its initial stages.
A new study has found that defects in the EMSY gene, similar to BRCA genes, spur cancer growth independently of BRCA1 and BRCA2 protection. The research suggests new treatment options for women with normal BRCA genes who develop breast and ovarian cancer.
The study found that the BRCA1 gene is required for the survival of blood forming stem cells, which could explain why patients with BRCA1 mutations do not have an elevated risk for leukemia. The researchers also suggest that these patients may have a tougher time with chemotherapy side effects.
Researchers found correlations between circulating tumor DNA (ctDNA) levels and ovarian cancer size, as well as patient response to treatment. The study used ctDNA carrying mutations in the TP53 gene to predict disease progression and treatment response, offering potential for early diagnosis and alternative treatment options.
Researchers developed a blood test to predict ovarian cancer patients' response to chemotherapy using tumour DNA levels. The test identified patients whose tumour DNA count dropped by more than half after one cycle of chemotherapy as those likely to respond well to treatment.
A 15-year study of prostate cancer patients found little difference in mortality between those screened annually and those not screened. However, the data suggest that personalized screening strategies could identify men at higher risk of death from other diseases.
Researchers identified a molecule called AXL which triggers the spread of an aggressive form of ovarian cancer. Blocking AXL may be an effective treatment option for patients with Mes subtype ovarian cancer.
Researchers at Case Western Reserve University developed a new method called InFlo to assess cell communication networks and identify disease-specific anomalies. InFlo predicts how cells send signals across networks to cause cancer or other disease, with applications in basic and translational research.
Researchers at Georgia Tech develop a targeted therapy using nanoparticles to deliver short interfering RNA that knocks down EGFR protein, leading to massive reduction or complete eradication of ovarian cancer tumors. The treatment, combined with chemotherapy, shows promising results in limited in vivo tests on mice.
Researchers at The Wistar Institute have developed a combination therapy that improves chemoresistance in ovarian cancer. BET inhibitors can suppress ALDH activity, making treatment more effective when used with cisplatin. This approach has shown extended survival rates and delayed tumor growth in mice.
Researchers at Boston University School of Medicine have discovered a potential treatment option for ovarian cancer by combining calpeptin with epigenetic inhibitors. The therapy shows promise in killing cancer cells and preventing their growth, offering new hope for women affected by the disease.
Research from Kumamoto University has discovered that a natural compound isolated from onions, onionin A, exhibits anti-ovarian cancer properties. ONA inhibits the growth of ovarian cancer cells and enhances the effects of anti-cancer drugs, making it a promising treatment option.
PharmaMar announces completion of Phase 3 pivotal study CORAIL with lurbinectedin (PM1183) for platinum-resistant ovarian cancer. The study demonstrates potential therapeutic alternative for patients who relapse after standard treatment. PharmaMar has successfully recruited 443 patients from over 100 hospitals in Europe and the USA.
New research from The Wistar Institute found that estrogen signaling is responsible for immunosuppressive effects in the tumor microenvironment across various cancers. This discovery paves the way for combining anti-estrogen therapy with immunotherapeutic treatments to extend survival in patients.
The ENGOT-OV16/NOVA trial shows niraparib significantly improves progression-free survival in recurrent ovarian cancer patients, with median survival rates up to 21 months. Niraparib also improves secondary endpoints, including time to first subsequent treatment and chemotherapy-free interval.
Researchers at The Wistar Institute discovered that BET inhibitors can suppress PD-L1 activity, a major therapeutic target in various tumors. This approach may reduce side effects while enhancing the immune response against cancer.
Global trends show a decline in ovarian cancer deaths in the EU and USA between 2002 and 2012, with declines also seen in Australia and New Zealand. The main reason is the use of oral contraceptives, which provide long-term protection against ovarian cancer.